About
Vimalan Biosciences develops selective Janus kinase (JAK) inhibitors targeting autoimmune and inflammatory diseases.
Explore Vimalan Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.